1st IEEE Workshop on Modeling, Simulation and Visual Analysis of Large Crowds in conjunction with 13th International Conference on Computer Vision (ICCV) 6-13 November, 2011, Barcelona, Spain The workshop encourages interdisciplinary (vision + graphics, evacuation dynamics + vision, etc.) contributions. Papers should describe original and unpublished work about the above or closely related topics. Each paper will receive 3 double blind reviews, which will then be moderated by the workshop chairs Workshop Goals Problems related to analysis of crowded scenes arise in a variety of contexts. A surveillance system installed in a city center may be interested in detecting individual objects that traverse the crowded scene to bootstrap its tracking module. At another location, a similar system may be interested in counting the number of people or estimating the density of crowd. Furthermore in context of object tracking, following individual person, a group of people, or the entire crowd may be of interest. Similarly event recognition systems may be interested in understanding what is happening in a scene by collecting local as well as global crowd statistics. Developing mathematical models of crowd movement and people interaction for simulation and modeling purposes is yet another area of interest. It is generally agreed that in low density environments the problems described above are well understood and relatively mature solutions exists to solve them. However computer vision research for moderate or high density environments is still in its early stages. Although attempts have been made in published literature to extend conventional computer vision algorithms designed for low density scenes in order to address some of the challenges of crowded scenes, these techniques alone appear insufficient to solve the new set of challenges posed by moderate to high density crowds. In recent years an encouraging new development has been the emergence of crowd motion and interaction models, originally developed in sociology, and adopted by computer graphics scientist for simulating realistic crowd behaviors. These models, social force model being one of them, depict crowd motion and interaction and can be used for simulating different emergent behaviors among a large number of agents or humans. Such crowd simulation systems are used for architectural and urban planning, enhancing virtual or training environments, animation characters for movies and games, as well as online virtual worlds (e.g. Second Life). In addition, group of researchers and practitioners in architecture, civil and fire safety engineering, physics and mathematics have been working on pedestrian and evacuation dynamics, which addresses issues related to whether the crowd behavior in an emergency situation is predictable and what are the different patterns occurring in pedestrian flows based on common rules. Their main goal is modeling and simulation of pedestrian and crowd movement as well as the dynamical aspects of evacuation processes. We believe computer vision research on visual analysis of crowds can greatly benefit by bringing together researchers from areas of computer vision, computer graphics, physics, and evacuation dynamics. Such a gathering will lay down a foundation for an integrated analysis-synthesis approach for crowd modeling, where complementary viewpoints and techniques from these areas are used to develop additional insight into crowd analysis, modeling and simulation problem. The focus will be on exchange of ideas on how to develop visual crowd analysis capabilities that make use of crowd simulation and evacuation dynamic techniques. As a byproduct, computer graphics and evacuation dynamics community will also benefit as this workshop will lead to improved methods for data-driven modeling, simulation and analysis of large-scale “heterogeneous crowds” using video recordings of real-world crowds. We hope to address following scientific questions and challenges through the workshop: What are the general principles that characterize complex crowd behavior of heterogeneous individuals? How can verifiable mathematical models of crowd motion and interaction can be developed based on these principles? How these general principles can be used to enhance performance of low level vision tasks such as object detection, tracking, and activity analysis in crowds? What are the possible problem areas that will benefit from simulation models for enhance video analysis capabilities (e.g. tracking, target acquisition across sensor gaps, and sensor hand-off techniques etc.). At what granularity level (micro, macro) should such analysis-synthesis approach be applied? =============================================================== Call for Papers Papers describing novel and original research are solicited in the areas related to visual analysis of crowded scenes. Topics of interest include but not limited to: Single and Multi-camera Tracking in High Density Crowds Event Analysis in Crowded and Cluttered Scenes Group Activity Analysis Action Recognition in Crowds Applications of Visual Crowd Analysis Systems Crowd Flow Analysis Data Driven Crowd Simulation Behavior Understanding Crowd Interaction Models and their Applications to Object Detection Tracking and Event Analysis Force based Models for Pedestrian Dynamics in Crowds. Image and Video Features for Crowd Modeling Datasets/ Model Validation/Calibration/Algorithm Testing/Annotation Techniques for Crowd Research =============================================================== Important Dates Submissions Deadline: July 15, 2011 Reviews Due: August 15, 2011 Camera Ready Papers: September 15, 2011 Workshop: November 7, 2011 ======================================================================== General Chairs Mubarak Shah (University of Central Florida) Dinesh Manocha (University of North Carolina) Rita Cucchiara (University of Modena and Reggio Emilia) =========================================================================== Program Chairs Saad Ali (SRI International Sarnoff) Nuno Vasconcelos (UC, San Diego) Fatih M. Porikli (MERL) Ko Nishino (Drexel University) Program Committee Anders Johansson (University College London) Norman Badler (Univ. of Pennsylvania) Bastian Leibe (RWTH) Antoni B. Chan (City University of Hong Kong) Song Chun Zhu (UCLA) Robert Collins (Pennsylvania State University) Andreas Schadschneider (University of Cologne) Stefania Bandini (University of Milano-Bicocca) Katsuhiro Nishinari (University of Tokyo) Josef Sivic (INRIA / ENS) Julien Pettre (INRIA) Rogerio Feris (IBM T.J. Watson) Gabriel Brostow (University College London) Omar Javed (SRI International Sarnoff) Ugur Gudukbay (Bilkent University) Majid Sarvi (Monash University) Xiaogang Wang (The Chinese University of Hong Kong) Rynson Lau (City University of Hong Kong) Maik Boltes (Jülich Supercomputing Centre) Daisuke Sugimura (University of Tokyo) Basim Zafar (Hajj Research Institute) Contact Saad Ali - saad dot ali at sri dot com
http://scienceblog.com/41428/study-finds-evidence-of-increased-lung-cancer-risk-among-tuberculosis-patients/ Study finds evidence of increased lung cancer risk among tuberculosis patients http://arrowsmith.psych.uic.edu/cgi-bin/arrowsmith_uic/edit_b.cgi Start A-Literature C-Literature B-list Filter Literature A-query: lung cancer risk C-query: tuberculosis The B-list contains title words and phrases (terms) that appeared in both the A and the C literature. 384 articles appeared in both literatures and were not included in the process of computing the B-list but can be viewed here . The results of this search are saved under id # 20954 and can be accessed from the start page after you leave this session. There are 1908 terms on the current B-list ( 521 are predicted to be relevant), which is shown ranked according to predicted relevance. The list can be further trimmed down using the filters listed in the left margin. To assess whether there appears to be a biologically significant relationship between the AB and BC literatures for specific B-terms, please select one or more B-terms and then click the button to view the corresponding AB and BC literatures. Use Ctrl to select multiple B-terms. id # 20954 started Sat Jan 1 23:46:35 2011 Max_citations: 50000 Stoplist: /var/www/html/arrowsmith_uic/data/stopwords_pubmed Ngram_max: 3 20954 Search ARROWSMITH A A_query_raw: lung cancer risk Sat Jan 1 23:47:09 2011 A query = lung cancer risk started Sat Jan 1 23:47:15 2011 A query resulted in 21471 titles 20954 Search ARROWSMITH C C_query_raw: tuberculosis Sat Jan 1 23:47:31 2011 C: tuberculosis 188094 A: pubmed_query_A 21471 AC: ( lung cancer risk ) AND ( tuberculosis ) 384 C query = tuberculosis started Sat Jan 1 23:47:32 2011 C query resulted in 50000 titles A AND C query resulted in 384 titles 21875 B-terms ready on Sat Jan 1 23:53:25 2011 Sem_filter: Chemicals Drugs 1908 B-terms left after filter executed Sun Jan 2 02:25:27 2011 B-list on Sun Jan 2 02:33:26 2011 1 highly active antiretroviral 2 docetaxel 3 paclitaxel 4 cox-2 5 active antiretroviral 6 transferase m1 7 vntr 8 carboplatin 9 transferase m1 t1 10 study docetaxel 11 fluorodeoxyglucose 12 fluorodeoxyglucose positron emission 13 receptor gene polymorphism 14 surfactant protein a 15 antiretroviral 16 nucleotide polymorphism 17 18f fluorodeoxyglucose 18 dna glycosylase 19 irinotecan 20 18f fluorodeoxyglucose positron 21 surfactant protein 22 sirolimus 23 tobacco control 24 oxidative dna 25 number tandem 26 n acetyltransferase nat2 27 endothelial growth factor 28 cytokine gene 29 etoposide 30 oxidative dna damage 31 mycophenolate mofetil 32 d-glucose positron emission 33 m1 t1 34 fluorodeoxyglucose uptake 35 phosphatidylinositol 3-kinase akt 36 alpha methylacyl coa 37 methylacyl coa racemase 38 clarithromycin 39 argon plasma coagulation 40 vegf 41 single nucleotide 42 minisatellite 43 f-18-fluorodeoxyglucose 44 ofloxacin 45 tyrosine kinase inhibitor 46 tacrolimus 47 polymorphism dna 48 idiopathic cd4 49 denaturing gradient gel 50 metalloproteinase-1 51 il-10 52 atomic bomb 53 vitamin d receptor 54 mycophenolate 55 bronchial carcinoid 56 polymorphism intron 57 inhaled corticosteroid 58 tobacco smoke risk 59 highly active 60 receptor polymorphism 61 chemokine 62 bleomycin induced pulmonary 63 dna adduct 64 phase study docetaxel 65 contrast enhanced 66 n acetyltransferase 67 budesonide 68 anti tnf 69 bronchial stump 70 interleukin-10 71 bleomycin induced 72 polymorphism cytochrome 73 matrix metalloproteinase-1 74 south african gold 75 smoking alcohol 76 t polymorphism 77 matrix metalloproteinase 78 pegylated liposomal doxorubicin 79 epoxide hydrolase 80 pseudogene 81 cisplatin 82 exposure silica 83 papillary thyroid 84 ganciclovir 85 d dimer 86 genetic polymorphism glutathione 87 silica dust 88 etoposide cisplatin 89 wood smoke exposure 90 cytokine gene polymorphism 91 il-12 92 fluoro-2-deoxy d-glucose 93 aromatic dna adduct 94 fludarabine 95 smoke risk 96 carboplatin paclitaxel 97 environmental tobacco smoke 98 differentiated thyroid 99 arylamine n acetyltransferase 100 african gold 101 uracil dna glycosylase 102 tobacco smoke 103 3-kinase akt pathway 104 genetic polymorphism cytochrome 105 anca associated 106 fibrin glue 107 cancer diesel exhaust 108 topotecan 109 uracil dna 110 cpg 111 inflammatory cytokine 112 statin 113 small cell bronchial 114 emission tomography f-18-fluorodeoxyglucose 115 diagnosis bronchial 116 coa racemase 117 serum tumor marker 118 phosphatidylinositol 3-kinase 119 matrix metalloproteinase-2 120 cisplatin versus 121 bisphosphonate 122 bronchial epithelial cell 123 cytokine level 124 antioxidant defence 125 tumor marker lung 126 central airway 127 didanosine 128 cyclooxygenase-2 129 cell bronchial 130 fumonisin 131 glutathione s-transferase m1 132 codon 133 liquid chromatography tandem 134 drug discovery 135 green tea 136 s transferase mu 137 papillary microcarcinoma thyroid 138 antiphospholipid 139 ambisome 140 cytokine gene expression 141 telomerase activity 142 fluoro-2-deoxy d-glucose positron 143 igfbp-3 144 atomic bomb survivor 145 adjuvant treatment 146 bronchial lesion 147 tissue inhibitor metalloproteinase 148 cigarette smoke 149 tiotropium 150 polymorphism cytochrome p450 151 anca 152 dna typing 153 imipenem 154 map kinase 155 smoke free 156 green tea extract 157 nucleotide polymorphism first 158 liposomal amphotericin 159 exposed silica 160 cyclooxygenase-2 expression 161 tobacco epidemic 162 tobacco smoke exposure 163 japanese atomic bomb 164 pro apoptotic 165 neuron specific enolase 166 zidovudine 167 factor binding protein 168 tumor marker 169 nucleotide polymorphism analysis 170 p38 mapk 171 matrix metalloproteinase-9 172 peroxisome proliferator activated 173 taxane 174 tnf alpha 175 glutathione s transferase 176 proliferator activated receptor 177 antiphospholipid antibody 178 liposomal amphotericin b 179 cytokine plasma 180 cd4 181 molecular weight heparin 182 smoke exposure 183 c polymorphism 184 polymorphism glutathione 185 d receptor 186 dmard 187 mannose binding lectin 188 dna alkyltransferase 189 surfactant protein d 190 cyfra carcinoembryonic antigen 191 metastatic hepatocellular 192 infection injecting drug 193 reactive nitrogen 194 paraffin embedded tissue 195 epitope 196 paraffin embedded 197 mitoxantrone 198 urokinase receptor 199 association allergy 200 mefloquine 201 cytokine expression 202 transcriptase polymerase chain 203 mannose binding 204 micronutrient 205 diesel exhaust exposed 206 dna vaccine 207 p53 protein 208 cyclosporine 209 exposure tobacco smoke 210 shock protein gene 211 gel microdrop 212 mpo 213 smoking alcohol drinking 214 il-8 215 ciprofloxacin 216 bcl-2 protein 217 lupus anticoagulant 218 quinone oxidoreductase 219 transferase mu 220 oligonucleotide microarray 221 ribavirin 222 histidine triad gene 223 wood smoke 224 coal dust 225 pro gastrin releasing 226 beta catenin 227 fragile histidine triad 228 cladribine 229 hpv dna 230 low cd4 231 b natriuretic peptide 232 cdna 233 dna ligase 234 tgf beta signaling 235 presentation pneumocystis carinii 236 etoposide cisplatin chemotherapy 237 18-fluorodeoxyglucose positron emission 238 cd40-cd40 ligand 239 role nitric oxide 240 cytochrome p450 241 t helper cytokine 242 growth factor receptor 243 value 18f fluorodeoxyglucose 244 antioxidant enzyme 245 cd4 t 246 glutathione s 247 tumor marker cea 248 hdl 249 sentinel 250 prevalence tobacco 251 serum carcinoembryonic antigen 252 ligase 253 intron 254 polymorphism first intron 255 mammalian target rapamycin 256 crack cocaine 257 conjugate vaccine 258 ofloxacin induced 259 ntp technical 260 neopterin a 261 heterocyclic amine 262 glutathione s-transferase 263 polymorphism glutathione s-transferase 264 pro brain natriuretic 265 cytokine patient 266 heat shock protein 267 racemase 268 versus paclitaxel 269 platinum 270 tnf 271 interleukin-8 272 dna adduct human 273 interleukin-1 receptor antagonist 274 nitinol stent 275 interleukin-18 276 hla dqa1 277 retroviral vector 278 formamidopyrimidine dna glycosylase 279 interleukin-2 receptor 280 antineutrophil cytoplasmic antibody 281 cytokine 282 uranium mining 283 lipocalin 284 growth factor binding 285 chemokine expression 286 arylamine 287 paraffin 288 rapamycin 289 protein gene polymorphism 290 gen 291 transplantation hla 292 silica dust exposure 293 effect tobacco 294 vitamin d 295 smoke a 296 dna non small 297 exposure tobacco 298 bronchial biopsy 299 treated fludarabine 300 human bronchial 301 splice 302 mapk 303 catenin 304 t helper 305 radioiodine 306 osteopontin 307 hnrnp 308 epoxide 309 telomerase 310 acrylonitrile 311 exposed silica dust 312 smoke 313 ts-1 314 igf i igf 315 sulfotransferase 316 analysis aromatic dna 317 adhesion molecule-1 318 polycyclic aromatic hydrocarbon 319 respirable coal dust 320 bronchial brushing 321 timp-1 322 visceral adipose tissue 323 untranslated region 324 vitamin d metabolite 325 tea polyphenol 326 diesel 327 polycyclic aromatic 328 sir 329 baseline characteristic 330 tumor necrosis factor 331 lipid peroxidation antioxidant 332 cytochrome p450 2e1 333 myeloperoxidase 334 therapy thalidomide 335 uptake 18f fluorodeoxyglucose 336 mitogen activated 337 shuttle vector 338 tgf beta1 339 galactomannan 340 plasma dna 341 raf-1 342 nuclear factor kappab 343 pigment epitheliopathy 344 mitogen activated protein 345 serum copper zinc 346 versus etoposide 347 alpha crystallin 348 enzyme linked 349 tobacco non 350 reverse transcriptase polymerase 351 based vaccine 352 carbon nanotube 353 diesel exhaust particle 354 inducible nitric oxide 355 level cea 356 adverse drug 357 18f fluorodeoxyglucose uptake 358 cytosolic phospholipase a2 359 copper nickel 360 plasminogen activator inhibitor 361 mrna human 362 growth factor beta1 363 human leukocyte antigen 364 bleomycin 365 vitamin mineral supplementation 366 cyclophosphamide doxorubicin 367 alpha antagonist 368 pneumococcal vaccine 369 expression inducible nitric 370 iron foundry 371 carcinoembryonic antigen 372 roxithromycin 373 serum galactomannan 374 heteroduplex 375 induced cytokine 376 acetyltransferase 377 thalidomide 378 heparin induced thrombocytopenia 379 airborne 380 neopterin 381 interleukin-10 production 382 transactivator 383 molecular chaperone 384 antigen sputum 385 il-6 386 tobramycin 387 kinase inhibitor 388 alternatively spliced 389 polyphenol 390 complementary alternative 391 tissue inhibitor 392 brain natriuretic peptide 393 3-kinase 394 ku 395 based blood test 396 polycyclic 397 cyclooxygenase 398 cyclophosphamide doxorubicin vincristine 399 metal lung 400 gastrin releasing peptide 401 antineutrophil 402 polymorphism untranslated region 403 ion trap 404 shock protein 405 intercellular adhesion molecule-1 406 urban rural 407 h quinone oxidoreductase 408 interleukin receptor 409 specific enolase nse 410 central airway obstruction 411 thrombomodulin 412 placoid pigment epitheliopathy 413 tandem 414 ethanol injection 415 multifocal placoid pigment 416 fluoro d-glucose 417 diesel exhaust 418 reverse transcriptase 419 admitted 420 nitric oxide synthase 421 p selectin 422 papillary mucinous 423 silicone breast 424 hepatocyte growth factor 425 metalloproteinase 426 interleukin-2 interferon 427 cea 428 tobacco 429 hbsag 430 hypoxia inducible factor 431 creb 432 c kit 433 murine model 434 oncoprotein 435 rural urban 436 oxide synthase gene 437 interleukin-1 beta 438 serum paraoxonase arylesterase 439 angiogenesis inhibitor 440 eicosanoid pathway 441 effect tobacco smoke 442 macrophage derived chemokine 443 marijuana 444 m csf 445 endonuclease 446 epitope vaccine 447 interferon gamma 448 murine lung 449 level cytokine 450 p h quinone 451 receptor family 452 phytohaemagglutinin 453 aromatic hydrocarbon 454 reactive nitrogen species 455 natriuretic peptide level 456 effect cigarette 457 stop smoking 458 tobacco alcohol 459 troponin 460 kinase signaling 461 novel vaccine 462 factor receptor lung 463 low dose methotrexate 464 adduct 465 triplex 466 laminin 467 prognostic indicator 468 pneumocystis carinii 469 oxygen radical 470 bronchial wash 471 transcription factor 472 multidrug transporter 473 interleukin-2 474 quartz 475 vaccine a 476 cxc chemokine 477 melanoma antigen 478 tissue inhibitor metalloproteinase-1 479 angiotensin receptor 480 azathioprine 481 tc-99m 482 aspirin ibuprofen 483 11beta hydroxysteroid dehydrogenase 484 i igf 485 arsenic drinking water 486 pollutant 487 renin angiotensin 488 nad p h 489 intron human 490 oxidative damage 491 cytokine cytokine 492 omeprazole 493 udp 494 cimetidine 495 antimicrobial 496 igf i 497 thymidylate 498 exhaust 499 hard metal 500 adjuvant 501 calcitriol 502 airborne particle 503 tgf beta 504 angiogenic 505 cysteine proteinase 506 human t lymphotropic 507 sulindac sulfone 508 antifungal 509 receptor tyrosine kinase 510 transferase t1 m1 511 deoxyglucose 512 eicosanoid 513 century 514 antifolate 515 metallothionein 516 bupivacaine 517 oxygen desaturation 518 helicase 519 lectin histochemistry 520 mucinous 521 control study tobacco http://arrowsmith.psych.uic.edu/cgi-bin/arrowsmith_uic/show_sentences.cgi Start A-Literature C-Literature B-list Filter Literature AB literature B-term BC literature lung cancer risk docetaxel tuberculosis 1: Concurrent chemoradiation therapy with docetaxel /cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study.2010 Add to clipboard 2: Dose-Volume Analysis of Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Cisplatinum and Etoposide With or Without Consolidation Docetaxel .2010 Add to clipboard 3: A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin -docetaxel , plus radical concurrent chemoradiotherapy with cisplatin -docetaxel , in patients with unresectable locally advanced non-small-cell lung cancer.2010 Add to clipboard 4: Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study.2010 Add to clipboard 5: Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.2009 Add to clipboard 6: Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.2009 Add to clipboard 7: Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.2009 Add to clipboard 8: The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel : a systematic review and meta-analysis.2009 Add to clipboard 9: Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial.2009 Add to clipboard 10: A Phase I trial of weekly docetaxel and topotecan for solid tumors.2008 Add to clipboard 11: Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers.2008 Add to clipboard 12: A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.2008 Add to clipboard 13: Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment.2008 Add to clipboard 14: Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.2008 Add to clipboard 15: Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel -induced febrile neutropenia: a prospective study.2007 Add to clipboard 16: A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer.2007 Add to clipboard 17: A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.2007 Add to clipboard 18: A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly.2007 Add to clipboard 19: Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.2007 Add to clipboard 20: Nail toxicity after treatment with docetaxel : a prospective analysis in patients with advanced non-small cell lung cancer.2007 Add to clipboard 21: Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naive patients with advanced non-small cell lung cancer.2007 Add to clipboard 22: Phase I and pharmacokinetic study of docetaxel , irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.2006 Add to clipboard 23: Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.2006 Add to clipboard 24: A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.2006 Add to clipboard 25: Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.2006 Add to clipboard 26: Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer.2006 Add to clipboard 27: Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.2006 Add to clipboard 28: Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).2005 Add to clipboard 29: Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).2005 Add to clipboard 30: Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.2005 Add to clipboard 31: Docetaxel for treatment of solid tumours: a systematic review of clinical data.2005 Add to clipboard 32: Docetaxel administration schedule: from fever to tears? A review of randomised studies.2005 Add to clipboard 33: A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study.2005 Add to clipboard 34: Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).2005 Add to clipboard 35: Two-dimensional radiotherapy and docetaxel in treatment of stage III non-small cell lung carcinoma: no good survival due to radiation pneumonitis.2004 Add to clipboard 36: Factors predicting docetaxel -related toxicity: experience at a single institution.2004 Add to clipboard 37: High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.2004 Add to clipboard 38: Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC.2004 Add to clipboard 39: Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.2004 Add to clipboard 40: Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.2003 Add to clipboard 41: Docetaxel -based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer.2003 Add to clipboard 42: Vesicant-type reaction due to docetaxel extravasation.2003 Add to clipboard 43: Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel -refractory metastatic breast cancer.2002 Add to clipboard 44: Gastrointestinal toxicity associated with weekly docetaxel treatment.2002 Add to clipboard 45: Nonneutropenic febrile episodes associated with docetaxel -based chemotherapy in patients with solid tumors.2002 Add to clipboard 46: Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.2002 Add to clipboard 47: Weekly docetaxel /paclitaxel in pretreated metastatic breast cancer.2002 Add to clipboard 48: Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel .2001 Add to clipboard 49: Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.2000 Add to clipboard 50: Docetaxel : a review of its use in non-small cell lung cancer.2000 Add to clipboard 51: Mesenteric venous thrombosis attributed to docetaxel .2000 Add to clipboard 52: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.1998 Add to clipboard 53: Docetaxel -induced subungual hemorrhage.1997 Add to clipboard 54: Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.1997 Add to clipboard 55: Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial.1997 Add to clipboard 1: 2008 Add to clipboard 2: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).2000 Add to clipboard
标签: 人群
